Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by A2 Biotherapeutics, Inc.
A2 Bio Announces First Patient Dosed in EVEREST-2 Phase 1 Clinical Trial of Novel Mesothelin Logic-Gated CAR T
May 16, 2024
From
A2 Biotherapeutics, Inc.
Via
Business Wire
A2 Bio to Highlight Progress of CAR T Clinical Programs in Three Poster Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
A2 Biotherapeutics, Inc.
Via
Business Wire
A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors
March 25, 2024
From
A2 Biotherapeutics, Inc.
Via
Business Wire
A2 Bio Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530 in Colorectal Cancer
March 04, 2024
From
A2 Biotherapeutics, Inc.
Via
Business Wire
A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 02, 2023
From
A2 Biotherapeutics, Inc.
Via
Business Wire
A2 Bio Announces Oral and Poster Presentations at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 16, 2023
From
A2 Biotherapeutics, Inc.
Via
Business Wire
A2 Bio Announces First Patient Dosed in Phase 1 Clinical Trial of A2B530, a Novel Cell Therapy for the Treatment of Colorectal, Pancreatic and Non-small Cell Lung Cancers
May 30, 2023
From
A2 Biotherapeutics, Inc.
Via
Business Wire
A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022
November 07, 2022
From
A2 Biotherapeutics, Inc.
Via
Business Wire
A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future Tmod™ CAR T Therapy
January 18, 2022
From
A2 Biotherapeutics, Inc.
Via
Business Wire
A2 Bio Provides First Preclinical Data Presentation for CEA and MSLN Programs, Including Trial Update at SITC 2021
November 12, 2021
From
A2 Biotherapeutics, Inc.
Via
Business Wire
A2 Bio to Highlight Program Updates in Two Presentations at SITC 2021
November 01, 2021
From
A2 Biotherapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.